The 28‐amino acid form of an APLP1‐derived Aβ‐like peptide is a surrogate marker for Aβ42 production in the central nervous system
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Surrogate markers for the Alzheimer disease (AD)-associated 42-amino acid form of amyloid-beta (Abeta42) have been sought because they may aid in the diagnosis of AD and for clarification of disease pathogenesis. Here, we demonstrate that human cerebrospinal fluid (CSF) contains three APLP1-derived Abeta-like peptides (APL1beta) that are generated by beta- and gamma-cleavages at a concentration of approximately 4.5 nM. These novel peptides, APL1beta25, APL1beta27 and APL1beta28, were not deposited in AD brains. Interestingly, most gamma-secretase modulators (GSMs) and familial AD-associated presenilin1 mutants that up-regulate the relative production of Abeta42 cause a parallel increase in the production of APL1beta28 in cultured cells. Moreover, in CSF from patients with pathological mutations in presenilin1 gene, the relative APL1beta28 levels are higher than in non-AD controls, while the relative Abeta42 levels are unchanged or lower. Most strikingly, the relative APL1beta28 levels are higher in CSF from sporadic AD patients (regardless of whether they are at mild cognitive impairment or AD stage), than those of non-AD controls. Based on these results, we propose the relative level of APL1beta28 in the CSF as a candidate surrogate marker for the relative level of Abeta42 production in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438 · cited 1×
“…produced via endoproteolysis by BACE, which cleaves b APP at the extracellular domain (Hussain et al, 1999; Sinha et al, 1999; Vassar et al, 1999; Yan et al, 1999), and by the presenilin (PS)– g -secretase complex (Francis et al, 2002; Yu et al, 2000), which cleaves b APP in the transmembrane…”
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 2×
“Although sulindac sulfide (Weggen et al, 2001) and compound-W (Okochi et al, 2006) have been shown to lower the relative A b 42 level to total A b , they did not cause a decrease in the relative APL1 b 28 level to total APL1 b (see Fig S7B–”
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271 · cited 1×
“Previous studies using PS1 mutant-transgenic mice report that the magnitude of the increase in the relative A b 42 level in cultured cells reflect the magnitude of increase in the brain (Borchelt et al, 1996; Citron et al, 1997).”
Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex
De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965 · cited 1×
“…et al, 1999; Sinha et al, 1999; Vassar et al, 1999; Yan et al, 1999), and by the presenilin (PS)– g -secretase complex (Francis et al, 2002; Yu et al, 2000), which cleaves b APP in the transmembrane domain (TM) (De Strooper, 2003; Edbauer et al, 2003; Kimberly et al, 2003; Takasugi et al, 2003).”
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · cited 2×
“However, in patients with AD, the relative ratio of A b 42 to total A b in CSF is lower (Andreasen et al, 1999; Jensen et al, 1999; Motter et al, 1995), probably because A b 42 in the brain is being cleared more rapidly from the soluble pool by an enhanced rate of deposition/aggregation.”
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582
Southwick, P. C., Yamagata, S. K., Echols, C. L., Higson, G. J., Neynaber, S. A., Parson, R. E., & Munroe, W. A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66010259.x · Cited by 89
Kauwe, J. S. K., Jacquart, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Goate, A. M. (2007) · Annals of Neurology · doi:10.1002/ana.21099 · Cited by 84 · cited 1×
“Kanta Yanagida et al. ) (Fukuyama et al, 2000; Ida et al, 1996; Kauwe et al, 2007; Mehta et al, 2000; Southwick et al, 1996; Wiltfang et al, 2007), the results indicate that the level of APL1 b in the CSF is similar to or even higher than that of A b .”
Cited by
Presenilins and -Secretase: Structure, Function, and Role in Alzheimer Disease
De Strooper, B., Iwatsubo, T., & Wolfe, M. S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006304 · Cited by 468
Lichtenthaler, S. F., Haass, C., & Steiner, H. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07248.x · Cited by 205
Self-citationOkochi, M., Tagami, S., Yanagida, K., Takami, M., Kodama, T. S., Mori, K., Nakayama, T., Ihara, Y., & Takeda, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.11.028 · Cited by 123
“, 2006) and APLP1-derived APL1b (Yanagida et al., 2009).”
BackgroundInfluentialSelf-citationHölttä, M., Minthon, L., Hansson, O., Holmén-Larsson, J., Pike, I., Ward, M., Kuhn, K., Rüetschi, U., Zetterberg, H., Blennow, K., et al. (2015) · Journal of Proteome Research · doi:10.1021/pr501076j · Cited by 100
Begcevic, I., Brinc, D., Brown, M., Martinez-Morillo, E., Goldhardt, O., Grimmer, T., Magdolen, V., Batruch, I., & Diamandis, E. P. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.027 · Cited by 81
Metadata
- Authors
- Yanagida, K., Okochi, M., Tagami, S., Nakayama, T., Kodama, T. S., Nishitomi, K., Jiang, J., Mori, K., Tatsumi, S., Arai, T., Ikeuchi, T., Kasuga, K., Tokuda, T., Kondo, M., Ikeda, M., Deguchi, K., Kazui, H., Tanaka, T., Morihara, T., Hashimoto, R., Kudo, T., Steiner, H., Haass, C., Tsuchiya, K., Akiyama, H., Kuwano, R., & Takeda, M.
- Venue
- EMBO Molecular Medicine
- Published
- 2009-07
- Volume
- 1
- Issue
- 4
- Pages
- 223-235
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2097094825
- Cited by
- 78
- References
- 9
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The 28‐amino acid form of an APLP1‐derived Aβ‐like peptide is a surrogate marker for Aβ42 production in the central nervous system. https://app.cochat.ai/papers/10.1002/emmm.200900026
- The paper
- Yanagida, K., Okochi, M., Tagami, S., Nakayama, T., Kodama, T. S., Nishitomi, K., Jiang, J., Mori, K., Tatsumi, S., Arai, T., Ikeuchi, T., Kasuga, K., Tokuda, T., Kondo, M., Ikeda, M., Deguchi, K., Kazui, H., Tanaka, T., Morihara, T., . . . Takeda, M. (2009). The 28‐amino acid form of an APLP1‐derived Aβ‐like peptide is a surrogate marker for Aβ42 production in the central nervous system. EMBO Molecular Medicine. https://doi.org/10.1002/emmm.200900026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.